BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New chemo cocktail aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It is for people with pancreatic cancer that can be removed or is borderline removable. Th…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New chemo cocktail aims to shrink pancreatic tumors before surgery
Disease control Recruiting nowThis study tests a chemotherapy combination called NALIRIFOX given before surgery to people with a type of pancreatic cancer that is close to major blood vessels but may still be removable. The goal is to shrink the tumor enough to make surgery more successful and lower the chanc…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
New radiation pulses aim to tame tough pancreatic tumors
Disease control Recruiting nowThis study tests a new way to deliver radiation called PULSAR, which gives short, powerful pulses of proton therapy every few weeks, adapting to changes in the tumor. It is for people with pancreatic cancer that has not spread widely. The goal is to improve local tumor control wh…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
Genetic blueprint may unlock better pancreatic cancer care
Knowledge-focused Recruiting nowThis study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will give blood, tissue, and fluid samples for genetic testing. Researchers want to see i…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated May 26, 2026 11:37 UTC
-
New study aims to unlock pancreatic Cancer's weaknesses
Knowledge-focused Recruiting nowThis study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers want to see how different drugs change tumor biology by comparing biopsies taken before and after treatment. The goal is not to cure the disease now, but to learn which drugs…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC